Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609724 | 0.97 | DRD2 (0.64) | HTR1ADRD2 | |
| SCHEMBL6608716 | 0.93 | DRD2 (0.55) | HTR1ADRD2 | |
| SCHEMBL6610328 | 0.89 | DRD2 (0.65) | HTR1ADRD2 | |
| SCHEMBL6609784 | 0.85 | DRD2 (0.69) | HTR1ADRD2 | |
| SCHEMBL6609064 | 0.82 | DRD2 (0.60) | HTR1ADRD2 | |
| SCHEMBL6611400 | 0.78 | DRD2 (0.66) | HTR1ADRD2 | |
| SCHEMBL6610264 | 0.77 | DRD2 (0.65) | HTR1ADRD2 | |
| SCHEMBL6608712 | 0.76 | DRD2 (0.59) | HTR1ADRD2 | |
| SCHEMBL7125220 | 0.76 | HTR1A (0.61) | HTR1ADRD2 | |
| SCHEMBL6738977 | 0.75 | HTR1A (0.67) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149087-B1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-04-07 | — | — | EP | claimed |
| US-6596722-B2 | Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders | H. LUNDBECK A/S (DK) | 2003-07-22 | — | — | US | claimed |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | claimed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| EP-1149087-B1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-6596722-B2 | Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders | H. LUNDBECK A/S (DK) | 2003-07-22 | — | — | US | disclosed |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | disclosed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885DRD2 2/4885 |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | HTR1A 51/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.